Company Overview and News

 
Equatorial Resources aims to invest $1.2 billion in Congo iron project

2016-11-23 reuters
BRAZZAVILLE Africa-focused Australian mining company Equatorial Resources Ltd (EQX.AX) will aim to invest around $1.2 billion to develop its Badondo iron ore project in Republic of Congo, the company said.

 
Annual Financial Report

2016-09-26 londonstockexchange
Mr Ian Middlemas                  Chairman Mr Benjamin Stoikovich        Director and CEO Ms Carmel Daniele               Non-Executive Director Mr Thomas Todd                    Non-Executive Director Mr Mark Pearce                       Non-Executive Director Mr Todd Hannigan                 Alternate Director

 
Annual Financial Report

2016-09-26 londonstockexchange
Unit 1C, Princes House 38 Jermyn Street London SW1Y 6DN United Kingdom Telephone:   +44 207 478 3900

 
Apollo Minerals Ltd to raise $4.4M, Ian Middlemas to become chairman

2016-05-11 proactiveinvestors.com.au
Apollo (ASX:AON) is a base, precious metals & iron ore explorer.  Apollo aims to enhance shareholder value by advancing projects through discovery, development & mining.

 
 
March 2016 Quarterly Report

2016-04-21 asx.com.au

 
 
Half Year Accounts

2016-03-07 asx.com.au

 
Appointment of Director

2016-02-25 asx.com.au

 
 
December 2015 Quarterly Report

2016-01-28 asx.com.au

 
Resignation of Director

2016-01-22 asx.com.au

 
Final Director's Interest Notice

2016-01-22 asx.com.au

 
 
Results of Meeting

2015-11-18 asx.com.au

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...